Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$88.1M
2 rounds on record
Latest round
$88.1M
Venture round · May 2018 · 8 yr ago
Team
113
US Form 5500 (plan participants) · Dec 2024
Backers
1
venBio Partners
The money's age
Long since its last round
100 months since the last round · not hiring
Momentum
0/100
no fresh signals
Funding rounds
RoundDateAmountInvestorsSource
Debt Financing Mar 2019 $39.6M — SEC Form D
Venture round May 2018 $88.1M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity PRECISION BIOSCIENCES INC sec
Founders and leadersfrom filings, registers and the company's site
Derek JantzExecutive Officer, DirectorSEC Form D
Matthew KaneExecutive Officer, DirectorSEC Form D
Abid AnsariExecutive OfficerSEC Form D
Jeff SmithExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Similar startupsby what they do, their industry and backers
Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent…
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
Paceline Bio runs the clinical ops layer behind biotech and pharma who want to move fast, from research to Phase 2: biospecimen collection…
VivoSenseVenture round $25M · 4 yr ago • 51-200 employees
VivoSense is the wearable sensor CRO for clinical trials, delivering digital endpoint infrastructure, scientific expertise, and end-to-end…
CuravitVenture round $11.4M · 3 yr ago • 51-200 employees
The Innovation CRO. Curavit partners with a variety of sponsors to design and execute innovative clinical trials, leveraging our Virtual…
AXONIS Therapeutics, Inc. is advancing breakthrough discoveries to develop first-in-class therapies for neurological disorders.

Overview

ARCUS Genome Editing. At Precision BioSciences, we are using our novel ARCUS genome-editing technology to develop a new class of medicines designed to overcome and potentially cure hard-to-treat conditions, including rare genetic diseases.

People

Derek Jantz
Executive Officer, Director
Matthew Kane
Executive Officer, Director
Abid Ansari
Executive Officer
Jeff Smith
Executive Officer
Tony Yao
Director
Robert Adelman
Director
Shalini Sharp
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Durham United States
HQ
Contact Us
302 East Pettigrew St., Durham, NC 27701
company site

Financials

Total raised
$127.6M
Latest round
Debt Financing
Funding rounds
2
Funding rounds
Round Announced Amount
Debt Financing 2019 $39.6M Details
Venture - Series Unknown 2018 $88.1M Details